The Value of Personalized Treatment Sequencing for Castration-Resistant Prostate Cancer

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 10, 2018 to August 10, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Astellas and Medivation, Inc., a Pfizer company, Bayer Healthcare and Sanofi Genzyme

Prostate cancer is the most commonly diagnosed noncutaneous cancer in men in the US and remains the second leading cause of cancer deaths among American men. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. CRPC occurs when patients' disease progresses despite castrate levels of testosterone. Recently updated guidelines on optimal sequencing and switching of antiandrogens, chemotherapy, immunotherapy, biomarkers and appropriate patient selection criteria in patients with CRPC have been produced and are being used to better treat the disease. The measurement of PSA level has also recently improved the diagnosis of prostate cancer and is used to monitor for disease recurrence. If the level of PSA is a high value, the more likely is the existence of this tumor. Since the approval of docetaxel, five additional therapeutic agents showing a survival benefit have been approved by the FDA in clinical trials. These include enzalutamide and abiraterone acetate, two agents designed specifically to affect the androgen axis; sipuleucel-T, which stimulates the immune system; cabazitaxel, a chemotherapeutic agent; alpharadin (or radium Ra 223 dichloride), an alpha particle-emitting radioactive therapeutic agent; and the new generation antiandrogen agent enzalutamide. These agents have been tested in multiple disease stages of prostate cancer to determine whether or when patients might benefit from each treatment.

Upon Completion of this activity, participants will be able to:

  • Assess how risk stratification and tumor information can inform sequencing in the management of castration-resistant prostate cancer (CRPC)

  • Discuss the clinical efficacy and safety data on investigational therapies for CRPC

  • Identify updates to clinical practice guidelines that reflect significant changes in the diagnosis and treatment of prostate cancer

  • Incorporate personalized treatment plans that reflect the best outcomes for CRPC patients that may include the use of combination and sequencing strategies

  • Provide strategies to manage treatment-related side effects in patients with CRPC

Faculty: Matthew R. Smith, MD, PhD
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center


Dr. Smith serves as a consultant for Amgen, Bayer, Janssen and Pfizer. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Astellas and Medivation, Inc., a Pfizer company, Bayer Healthcare and Sanofi Genzyme

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue